key: cord-0967703-5bxczs35 authors: Kapa, D Ramaiah; Mohamed, Ahmed Jamsheed title: Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-East Asia date: 2020-12-22 journal: Int Health DOI: 10.1093/inthealth/ihaa056 sha: cd7cb460f80363303377872a0c48d002c8690028 doc_id: 967703 cord_uid: 5bxczs35 BACKGROUND: The South-East Asia regional programme to eliminate lymphatic filariasis (LF) was launched in 2000. This study presents the progress and impact of the programme in the region. METHODS: Mass drug administration (MDA) and morbidity management data were accessed from the WHO preventive chemotherapy databank. The status of the programme in the nine South-East Asia countries was reviewed and progress was assessed. The impact of the programme on LF disease burden was estimated on the basis of the effectiveness of the MDA drugs against microfilaraemia and chronic disease. RESULTS: Under the MDA programme, 8.1 billion treatments were delivered in nine countries and 5.7 billion treatments were consumed by the target population during 2001–2018. Three of nine countries eliminated LF. Bangladesh is poised to reach its elimination goal by 2021. In the other five countries, 38–76% of intervention units completed intervention and surveillance is in progress. The MDA programme prevented or cured 74.9 million infections, equivalent to an 84.2% reduction. Close to 1 million lymphoedema patients and 0.5 million hydrocele patients were reported and are being provided with the minimum package of care. CONCLUSIONS: The South-East Asia region's LF elimination programme reduced the burden of LF appreciably and is moving towards achieving the elimination goal in the next 8–10 y. Lymphatic filariasis (LF) is a neglected tropical disease (NTD) widely prevalent in the South-East Asia region (SEAR). Chronic disease manifestations such as lymphoedema and hydroceles are disfiguring and disabling and inflict social and economic loss and stigma and poverty. The region consists of nine endemic countries with a population of 1.98 billion, of which 853 million (43%) live in known LF endemic areas. The nine endemic countries are India, Indonesia, Myanmar, Bangladesh, Nepal, Sri Lanka, Timor-Leste, Thailand and Maldives. The LF burden was very high in SEAR, accounting for, as of 2000, 70.0 million of the 129.8 million (54%) globally infected population. 1 The economic impact of LF is significant and India alone suffers an annual loss of nearly US$ 1 billion. 2 Amidst the escalating LF burden, the Global Programme to Eliminate LF (GPELF), launched in 2000, 3 provide the tools and strategies to counter the disease in the region. The scalability of its twin strategies, (1) mass drug administration (MDA) to interrupt transmission and (2) morbidity management and disability prevention (MMDP) measures to alleviate suffering 4 have attracted the attention of governments. Following the guidance of GPELF, the SEAR countries initiated the National Programmes to Eliminate LF (NPELF), with 2020 as the target date. The NPELF consists of (1) formation of a national taskforce, (2) mapping of endemic areas, (3) implementation of MDA and MMDP in endemic areas, (4) monitoring and evaluation and post-MDA transmission assessment surveys, (5) preparation of an LF elimination validation dossier and its submission by countries to WHO, (6) review of the dossier by a WHO-constituted expert group and an acknowledgement of countries claiming to have eliminated LF and (7) post-validation surveillance. The national programmes were backed by extensive preparatory work and research studies on mapping, MDA, surveillance and MMDP. [5] [6] [7] [8] [9] Elimination of LF, along with other NTDs, has been a regional flagship programme of WHO since 2015. This paper presents Table 1 ). The gap between the number of treatments delivered and consumed was due to some people refusing to participate in treatment on account of a fear of adverse events, poor perceived benefits of treatment, the personal health status of individuals and poor drug delivery in some places. 12 The regional reported treatment coverage varied from year to year ranging from 55.7% in 2006 to 88.7% in 2002. The average number of treatments delivered per person was 9.43 and treatments consumed was 6.7. In 66% of IUs in the region, MDA was completed and stopped after meeting the Transmission Assessment Survey (TAS) criteria. In countries where MDA is in progress, 38% to 76% of IUs (Table 1) The underlying analyses presented in Table 2 show that there were an estimated 8.1 million lymphoedema cases and 5.6 million hydrocele cases in SEAR as of 2018, spread over hundreds of thousands of communities. The MMDP strategy envisages providing the minimum package of care to all chronic disease patients, which should be evident from surveys on the quality of lymphoedema services. To implement such a huge MMDP programme is challenging, particularly in countries with a high disease burden and vast endemic areas. 13, 14 As of 2018, 944 957 lymphoedema patients and 452 891 hydrocele patients were reported by the countries' programmes. 10 Enlisting the patients in all IUs using robust methodologies 15, 16 and expansion of the MMDP measures remains a priority for larger countries in the region. This has been well accomplished in Bangladesh, where more than 30 616 lymphoedema patients and 12 824 hydrocele patients were identified and are being provided with the recommended package of care. 16 Countries with a relatively low disease burden such as Maldives, Thailand and Sri Lanka met the MMDP criteria required for validation of the elimination of LF. Three countries in the region, namely, Maldives, Sri Lanka 17 and Thailand, 18 met the LF elimination criteria and were validated by the WHO. All three countries eliminated LF by 2017, with five to six rounds of effective MDA (only the Narathiwat province in Thailand required nine rounds). Commitment, good health systems, effective implementation of intervention and surveillance measures enabled these countries to accomplish elimination relatively early. Bangladesh has completed the intervention measures and most of the surveillance and MMDP activities 16, 19 and is to submit the LF elimination dossier to WHO shortly. Various provinces of the other five countries, namely, India, 20-22 S18 of S21 Indonesia, 11 Myanmar, 23,24 Nepal 25 and Timor-Leste, 11 implemented multiple rounds of MDA. They are at different levels of progress and are making sustained efforts to reach the LF elimination goal in forthcoming years ( Table 1 ). The impact of the MDA programme on LF infection is assessed using a model described earlier. 1 The 18 y (2001-2018) of the MDA programme in the region, under which 5.7 billion treatments were consumed, prevented or cured 74.9 million infections, which include microfilaria (Mf) carriers and chronic disease patients. This is equivalent to an 84.2% reduction in infections (Table 2) compared with the actual number of infections (89.0 million) that would have been prevalent had there been no MDA intervention. Bangladesh, a lower to middle income country, stands out in the region by virtue of some best practice followed by the NPELF. Proactive programme leadership, good teamwork and consistent support by the Ministry of Health enabled the programme to move closer to elimination of LF. 16, 19 Some of the best practice of the programme includes (1) quality MDA and monitoring and evaluation practices, (2) robust delineation of endemicity and assessment of chronic disease burden in 19 endemic districts 16 and 15 uncertain districts 26 and implementation of MMDP measures and (3) active partnership with stakeholders and undertaking programme-specific research studies. [27] [28] [29] [30] The NPELF is likely to submit the dossier by 2021 for validation of elimination of LF, globally the first large high burden country to do so. The triple drug therapy of ivermctin plus DEC plus albendazole (IDA), shown to be more efficacious than the currently used two-drug therapy (DEC plus albendazole), [31] [32] [33] was introduced into the region to accelerate the elimination of LF. Studies showed that all individuals treated with triple drug therapy remained Mf negative after 1 y compared with 1 of 12 individuals on the two-drug regimen 31 and that this impressive Mf clearance was sustained for as long as 3 y. 33 This instilled confidence that triple drug therapy will be able to eliminate LF with fewer rounds of MDA compared with two-drug therapy and that it will accelerate elimination of LF. 32, 34 Timor-Leste deployed the triple drug therapy in the entire nationwide MDA of 2019 and is the first country to do so globally. The programme covered 1.3 million and reported 76% treatment coverage. In 2018, India piloted IDA therapy in four districts with a population of >10 million and expanded this to 19 districts in 2019. The country has ambitious plans to expand further to all eligible districts. Indonesia, Myanmar and Nepal also have plans to introduce IDA therapy, particularly in those districts that fail in TAS. Implementation of triple drug therapy requires recalibration of some programme activities such as administering the drugs according to height as well as extensive social mobilisation and microplanning. Timor-Leste and India were able to make such changes, paving the way for other countries in the region. The community-level impact of the triple drug therapy is being evaluated. To achieve elimination of LF in the region, the following challenges need to be addressed: (1) Treatment coverage has been suboptimal in some districts across the large countries, 35, 36 particularly where health systems are weaker. So steps should be taken to attain effective treatment coverage. (2) Hotspots and residual infection [37] [38] [39] in bancroftian and brugian filariasis endemic areas, which is seen in up to 34% of the communities in some situations, 38 remain a threat. To overcome this, post-TAS surveillance methods 40, 41 should be standardised and introduced into the programme to eliminate residual microfilaraemia. (3) Comprehensive enlisting of chronic disease cases across the districts of large countries through robust and feasible methods 15, 16 and providing them with the minimum package of care by strengthening the necessary components of primary healthcare systems is required to meet the MMDP criteria to validate elimination of LF. (4) A considerable proportion of the at-risk population lives in urban areas where MDA implementation and treatment coverage have been suboptimal. 35 A strategy to assess LF distribution and implementation of intervention measures in needy localities is required. (5) The LF status of some districts is uncertain 42 and needs to be reassessed using robust sampling strategies. 43 And it should be examined if some of these districts require intervention measures. (6) Continuous advocacy remains a high priority for the region to sustain the governmental and donor support to the programme for a sufficiently long time. (7) The ongoing pandemic of COVID-19 has disrupted community-based interventions, including MDA and pre-TAS/TAS assessment, in many IUs across countries. The effect of COVID-19 on global economies will also change the NTD funding landscape, both locally and globally, which may impact the LF elimination programmes in the region. So stakeholders need to work together to sustain the priority activities and gains of the NPELF. The SEAR has made tremendous progress towards elimination of LF and has already reduced the disease burden significantly. The larger countries in the region are likely to complete intervention in 3-5 y and surveillance in another 4 y. The region is well placed to achieve the goal of LF elimination by 2028-2030. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease The economic burden of lymphatic filariasis in India The global programme to eliminate lymphatic filariasis World Health Organization. Lymphatic Filariasis. Global Programme to Eliminate Lymphatic filariasis Mapping of lymphatic filariasis in India Mapping of lymphatic filariasis in Nepal Mass drug administration to eliminate lymphatic filariasis in India Lymphatic filariasis and Brugia timori: prospects for elimination A qualitative study on the feasibility and benefits of food hygiene measures practiced by patients with brugian filariasis World Health Organization. Neglected Tropical Diseases. PCT Databank A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects Experience of a communitybased lymphoedema management programme for lymphatic filariasis in Odisha state, India: An analysis of focus group discussions with patients, families, community members and programme volunteers Evaluating the burden of lymphedema due to lymphatic filariasis in 2005 in Khurda district, Odisha state, India Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals World Health Organization, South-East Asia How Thailand eliminated lymphatic filariasis as a public health problem The significant scale up of Transmission Assessment Surveys 'TAS' for endgame surveillance of lymphatic filariasis in Bangladesh: One step closer to the elimination goal of 2020 National Vector Borne Disease Control Programme. Director General of Health Services. Ministry of Health & Family Welfare Elimination of diurnally sub-periodic Wuchereria bancrofti in Andaman and Nicobar Islands, India, using mass DEC-fortified salt as a supplementary intervention to MDA Elimination of lymphatic filariasis in India-a successful endeavour Mapping and modelling the impact of mass drug administration on filariasis prevalence in Myanmar Rapid progress towards elimination of lymphatic filariasis in endemic regions of Myanmar as a result of 16 years of anti-filarial activities Impact of mass drug administration for elimination of lymphatic filariasis in Nepal Methods for assessing lymphatic filariasis transmission in low endemic areas of Bangladesh: one step closer to the elimination goal Clinical case estimates of lymphatic filariasis in an endemic district of Bangladesh after a decade of mass drug administration Community-based field implementation scenarios of an SMS reporting tool for lymphatic filariasis case estimates in Molecular xenomonitoring for Wuchereria bancrofti in Culex quinquefasciatus in two districts in Bangladesh supports transmission assessment survey findings An enhanced self-care protocol for people affected by moderate to severe lymphedema Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study A trial of triple-drug treatment for lymphatic filariasis Alternative mass drug administration regimens to eliminate lymphatic filariasis Coverage of and compliance with mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review Improving coverage and compliance in mass drug administration for the elimination of LF in two 'endgame' districts in Indonesia using micronarrative surveys The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region Epidemiological assessment of eight rounds of mass drug administration for lymphatic filariasis in India: implications for monitoring and evaluation A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India Mapping is a prerequisite for elimination of filariasis and effective targeting of filarial 'hot spots'. Pathog Glob Health Results of a confirmatory mapping tool for lymphatic filariasis endemicity classification in areas where transmission was uncertain in Ethiopia Authors' contributions: KDR prepared the first draft of the manuscript and analysed the data. AMJ identified and separated data and created a database. Both authors read, reviewed and approved the final manuscript. KDR is the guarantor of the paper. The publication of the papers within this supplement were supported by MSD, GSK and Eisai through the Mectizan Donation Program (MDP) and the Global Alliance for LF Elimination (GAELF). Ethical approval: The work was approved by the South-East Asia Regional Office, WHO, New Delhi, India.